...
机译:美国国家生物化学临床化学实验室医学实践指南在肝癌,膀胱癌,宫颈癌和胃癌中使用肿瘤标志物
Catharine M. Sturgeon,1* Michael J. Duffy,2 Barry R. Hofmann,3 Rolf Lamerz,4 Herbert A. Fritsche,5 Katja Gaarenstroom,6 Johannes Bonfrer,7 Thorsten H. Ecke,8 H. Barton Grossman,9 Peter Hayes,10 Ralf-Thorsten Hoffmann,11 Seth P. Lerner,12 Florian Löhe,13 Johanna Louhimo,14 Ihor Sawczuk,15 Kazuhisa Taketa,16 and Eleftherios P. Diamandis3NACB SUB-COMMITTEE MEMBERSLiver Cancer: Rolf Lamerz, Chair, Peter Hayes, Ralf-Thorsten Hoffmann, Florian Löhe, and Kazuhisa Taketa, Bladder Cancer: Herbert A. Fritsche, Chair, Thorsten H. Ecke, H. Barton Grossman, Seth P. Lerner, and Ihor Sawczuk, Cervical Cancer: Katja Gaarenstroom, Chair, Johannes Bonfrer, Gastric Cancer: Johannes Bonfrer, Chair, and Johanna Louhimo1 Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK, 2 Department of Pathology and Laboratory Medicine, St Vincent's University Hospital and UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, 3 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada, 4 Department of Medicine, LMU-Klinikum- Grosshadern, University of Munich, Germany, 5 Department of Laboratory Medicine, the University of Texas M. D. Anderson Cancer Center, Houston, TX, 6 Department of Gynecology, Leiden University Medical Center, Leiden, the Netherlands, 7 Department of Clinical Chemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands, 8 Department of Urology, Helios Hospital, Bad Saarow, Germany, 9 Department of Urology, the University of Texas M. D. Anderson Cancer Center, Houston, TX, 10 Scottish Liver Transplant Unit, Department of Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK, 11 Department of Clinical Radiology, LMU-Klinikum-Grosshadern, University of Munich, Germany, 12 Department of Surgery, LMU-Klinikum-Grosshadern, University of Munich, Germany, 13 Department of Urology, Baylor College of Medicine, Houston, Texas, 14 Department of Clinical Chemistry, Helsinki University Central Hospital, Finland, 15 Department of Urology, Hackensack University Medical Center, Hackensack, New Jersey,16 Clinical Trial Center, Brain Attack Center, Oota Memorial Hospital, Fukuyama, Japan.* Address correspondence to this author at: the Department of Clinical Biochemistry, Royal Infirmary, Edinburgh EH16 4SA, UK. Fax µ44-1311-242-6882, e-mail C.Sturgeon@ed.ac.uk.Received July 3, 2009, accepted December 11, 2009.Previously published online at DOI: 10.1373/clinchem.2009.133124Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employment or Leadership: H.A. Fritsche, MD Anderson Cancer Center.Consultant or Advisory Role: H.A. Fritsche, Tosoh, Gen Probe, Cepheid, OncImmune, and Health Discovery Corp, J. Bonfrer, Dia- Genic ASA, H.B. Grossman, Abbott Molecular.Stock Ownership: H.A. Fritsche, Health Discovery Corp and Third Nerve.Honoraria: C.M. Sturgeon, Abbott Diagnostics, Beckman Coulter Diagnostics, Becton Dickinson Diagnostics, DAKO, Roche Diagnostics, Siemens Diagnostics, Tosoh Biosciences, and Wallac Oy, M.J. Duffy, Abbott Diagnostics, H.B. Grossman, Abbott Molecular.Research Funding: M.J. Duffy, Randox Laboratories, H.A. Fritsche, Roche, Tosoh, Veridex, and Oncovista, S. Lerner, Pfizer, Eli Lilly.Expert Testimony: None declared.Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.,;
机译:美国国家临床生物化学研究院实验室医学在肝癌,膀胱癌,宫颈癌和胃癌中使用肿瘤标志物的实践指南
机译:美国国家临床生物化学研究院实验室医学在睾丸癌,前列腺癌,结直肠癌,乳腺癌和卵巢癌中使用肿瘤标志物的实践指南
机译:美国国家临床生物化学研究院实验室医学实践指南中使用肿瘤标记物的质量要求
机译:干细胞样标志物CD133或CD24在胃癌循环肿瘤细胞不同亚群中的表达及临床意义的试验研究
机译:急诊医学临床实践指南的质量评估
机译:美国国家临床生物化学研究院实验室医学实践指南中使用肿瘤标记物的质量要求
机译:美国国家临床生物化学研究院实验室医学在睾丸癌,前列腺癌,结肠直肠癌,乳腺癌和卵巢癌中使用肿瘤标志物的实践指南。